Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Leukotriene (LT) B4 is a potent neutrophil chemoattractant and also stimulates eosinophils in vitro, but its role in asthmatic inflammation is unknown. METHODS: The effect of the novel LTB4 receptor antagonist, LY293111, was examined using allergen challenge as a model for asthmatic inflammation in 12 atopic asthmatic subjects in a double blind placebo controlled crossover trial. Subjects with an established early (EAR) and late asthmatic response (LAR) to allergen at screening received oral LY293111 in a dose of 112 mg three times daily for seven days or placebo before further allergen challenge. Each treatment was separated by a washout period of 28 days. Individuals underwent histamine challenge one hour before and three hours after allergen challenge. Bronchoalveolar lavage (BAL) fluid was obtained at bronchoscopy 24 hours after allergen challenge. RESULTS: There was no difference in baseline lung function, EAR, LAR, or in airway responsiveness to histamine before and after allergen between placebo and LY293111. By contrast, treatment with LY293111 significantly reduced the number of neutrophils in BAL fluid expressed as both absolute cell numbers and percentage cell differential counts: absolute cell counts, median (range) 0.04 (0.02-0.15) x 10(6) after LY293111, 0.09 (0.02-0.43) x 10(6) after placebo; percentage differential cell counts 0.35 (0.1-2.0) after LY293111, 0.80 (0.1-3.6) after placebo (p < 0.05). Eosinophils, macrophages, and lymphocytes in BAL fluid did not differ between treatments. There was a significant reduction in the concentration of myeloperoxidase (MPO) with both placebo (16 (6.6) ng/ml) and LY293111 (3.5 (1.8) ng/ml) and of LTB4 (placebo 4.6 (1.2) pg/ml, LY293111 2.2 (0.2) pg/ml). Concentrations of LTC4 and interleukin 8 were reduced, although not significantly, whereas concentrations of interleukin 6, GM-CSF, and TNF-alpha were unchanged by LY293111. CONCLUSIONS: These results demonstrate an influence of LTB4 on neutrophil influx and activation in the airway following allergen challenge. Despite this anti-inflammatory effect, there was no measured physiological benefit and this questions the functional role of the neutrophil in the pathophysiology of allergen induced asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis (1990) · doi:10.1056/nejm199009063231006 · Cited by 1,200
Cited by
Treatment of Asthma with Drugs Modifying the Leukotriene Pathway
Drazen, J. M., Israel, E., & O'Byrne, P. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400306 · Cited by 820
Inflammatory Mediators of Asthma: An Update
Barnes, P. J., Chung, K. F., & Page, C. P. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01381-4 · Cited by 717
Self-citationBLT1 and BLT2: the leukotriene B4 receptors
Tager, A. M., & Luster, A. D. (2003) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00073-5 · Cited by 366
Pharmacology of the Eosinophil
Giembycz, M. A., & Lindsay, M. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01404-2 · Cited by 351
Barnes, P. J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1524 · Cited by 280
Self-citationBARNES, P. J. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.03721.x · Cited by 270
Self-citationThe role of eosinophils and neutrophils in inflammation
Sampson (2000) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2000.00092.x · Cited by 259
Severe asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174
Self-citationLee, E. K. S., Gillrie, M. R., Li, L., Arnason, J. W., Kim, J. H., Babes, L., Lou, Y., Sanati-Nezhad, A., Kyei, S. K., Kelly, M. M., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.11.009 · Cited by 89
Metadata
- Authors
- Evans, D. J., Barnes, P. J., Spaethe, S. M., van Alstyne, E. L., Mitchell, M. I., & O'Connor, B. J.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 1996-12-01
- Volume
- 51
- Issue
- 12
- Pages
- 1178-1184
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2123186852
- Cited by
- 175
- References
- 1
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.